With importation on tap, Grassley urges FDA to inspect foreign drug plants 'unannounced'

Chuck Grassley
Sen. Chuck Grassley is calling on the Trump administration to resume “unannounced” inspections of drug manufacturing plants in foreign countries, specifically citing India and China. (Gage Skidmore)

Sen. Chuck Grassley is all for importing drugs to drive down prices. He just wants the Trump administration to stop warning foreign manufacturing plants that FDA inspectors are on their way—particularly in India and China.

In a letter sent Wednesday to Health and Human Services Secretary Alex Azar and FDA acting Commissioner Norman Sharpless, the Republican senator from Iowa said surprise inspections were needed as the pharmaceutical production sites make most of the ingredients for drug products sold in the U.S.

"As you are aware, I believe that drug importation will help to reduce drug costs for American consumers and patients," Grassley wrote. "However, I have also noted that my position is predicated on the FDA ensuring the safety and efficacy of those drugs."

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

About 80% of active pharmaceutical ingredients used in U.S. pharmaceuticals are manufactured overseas with the majority of APIs produced in China and India, yet the FDA only inspected one in five registered human drug production plants abroad last year, Grassley said.

RELATED: O, Canada! Like his across-the-aisle rivals, Trump looks to imports to cut drug costs

As the administration opens the door to foreign imports, that needs to change, he said. “I strongly encourage the administration’s demonstration projects to include unannounced inspection in foreign manufacturing facilities to determine whether they meet the required active pharmaceutical ingredients and drug quality and safety standards to include sufficient record-keeping, testing and protections against counterfeiting,” Grassley wrote.

In 2014 the FDA unveiled a pilot program in India, the senator noted, that cut out advance notice of an inspection in lieu of either short notice or an unannounced visit. That program also provided that FDA inspectors arrange their travel through U.S. embassies versus FDA offices or manufacturer-arranged travel so there was more secrecy ahead of an inspection.

Under that program, the FDA saw a 60% increase in the number of warnings it issued to manufacturers, he said. The pilot program ended in 2015.

Grassley’s call comes in the wake of news that the Pentagon is eyeing China’s API production as a potential health and security issue. 

Following a series of FDA recalls of “sartan” active ingredients used in making generic blood pressure medications, the Defense Health Agency said it was scrutinizing increased Chinese production of the API behind a range of blood pressure drugs that include losartan and valsartan as a health threat to military personnel who use the drugs.

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…